March 19, 2024CorporateTerumo Blood and Cell Technologies partners with CiRA Foundation to develop automated iPS cell manufacturingiPS cell manufacturing organization researchers to integrate Terumo Blood and Cell Technologies’ Quantum Flex, expertise through collaboration
March 11, 2024FinancialNotice Concerning the Status and Completion of the Acquisition of Own Shares and Cancellation of Treasury Stock (PDF 130.35 KB)
March 11, 2024FinancialNotice Concerning Partial Amendment to “Notice Concerning Share Split and Partial Amendment to the Articles of Incorporation” (PDF 115.61 KB)
The Latest Materials 3rd Quarter Financial Results for FYE 3/2024 February 07, 2024 Financial Statements IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2024 (PDF 403.23 KB) Presentation Material Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2024 (PDF 1.37 MB) Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2024 (FY2023)(with note) (PDF 682.62 KB) Additional Information Revenue by Segment (PDF 267.56 KB) Revenue by Segment (Excel 229.07 KB) Q&A Q&A Session at the Financial Results Briefing for the Third Quarter of Fiscal Year Ending March 31, 2024 (PDF 210.94 KB) Webcast Listen to the Webcast Financial Statements /investors/library/financial-statements Presentations /investors/library/presentations Terumo Report /investors/library/annual-reports Sustainability /sustainability Corporate Governance /about/governance Consolidated Financial Statements /investors/library/financial Adobe Reader is required for viewing PDF files. Download Adobe Reader
IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2024 (PDF 403.23 KB)
Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2024 (FY2023)(with note) (PDF 682.62 KB)
Q&A Session at the Financial Results Briefing for the Third Quarter of Fiscal Year Ending March 31, 2024 (PDF 210.94 KB)